Drug stability Dotaz Zobrazit nápovědu

Reset

1 302 záznamů v PubMed

Článek

PROBL'EMY STABILITY L'E CIV Z HLEDISKA KONTROLY
[PROBLEMS OF DRUG STABILITY FROM THE VIEWPOINT OF CONTROL]

VACEK, J
Autor VACEK, J

Ceskoslovenska farmacie. 1963 Dec ; 12 () : 524-8.

Cesk Farm
ISSN 0009-0530
Zdroj

Klíčová slova
CHEMISTRY, PHARMACEUTICAL *, CZECHOSLOVAKIA *, DRUG INDUSTRY *, DRUGS *, STATE MEDICINE *,
MeSH
farmaceutická chemie * MeSH
farmaceutický průmysl * MeSH
farmacie * MeSH
léčivé přípravky * MeSH
lidé MeSH
stabilita léku * MeSH
státní lékařství * MeSH
Check Tag
lidé MeSH
Publikační typ
časopisecké články MeSH
Geografické názvy
Československo MeSH
Názvy látek
léčivé přípravky * MeSH

Článek

Sledovanie stability roztokov peroxidu vodíka
[Examination of the stability of hydrogen peroxide solutions]

Reliable stabilization of the pharmaceutical preparation and the active ingredient remains one of the ...

Ceska a Slovenska farmacie. 2004 Sep ; 53 (5) : 261-3.

Ceska Slov Farm
ISSN 1210-7816
Zdroj

Reliable stabilization of the pharmaceutical preparation and the active ingredient remains one of the most important problems of world pharmacy because pharmaceutical preparations are not systems which are stable without limitation. The patient must receive a quality drug and that is why the question of stability is paid grest attention to not only in research and development, industrial manufacture, but also in distribution. The measure of stability is the expiration period. Diluted solution of hydrogen peroxide (3% solution) still belongs to the most widely used and at the same time the most easily accessible disinfectants. In practice it is common both in Slovakia and abroad. It is used in several concentrations. One of its most important disadvantages is its limited stability, which markedly decreases its expiration period. The present paper investigates the stability of hydrogen peroxide solutions of routinely used concentrations (3%, 6%, and 10%) without and with a stabilizing additive (phenacetin) prepared in the pharmacy and stored under different conditions for the period of their expected usability. The content of hydrogen peroxide was assayed by the pharmacopoeial method in 7-day time intervals. All concentrations of 3%, 6%, and 10% hydrogen peroxide were found to fulfil the conditions for stability in the period of time under study. Their concentration did not fall below the limit od 90% of the content of the active ingredient, and storage under decreased temperature proved to be more suitable. Storage of hydrogen peroxide in the light is inadmissible. When the conditions of storage are observed, the required therapeutic effect of hydrogen peroxide solution can be expected for the period of three months.

Článek

Sledování stability lékové formy prípravku soluglaucit
[Study on the stability of the preparation Soluglaucit]

Blazek, J
Autor Blazek, J

Ceskoslovenska farmacie. 1966 Nov ; 15 (9) : 478-82.

Cesk Farm
ISSN 0009-0530
Zdroj

Článek

Stúdium stability mastí s obsahom fluorkortikoidov
[Study of stability of fluorcorticoid-containing ointments]

Ceskoslovenska farmacie. 1969 Nov ; 18 (9) : 445-50.

Cesk Farm
ISSN 0009-0530
Zdroj

Článek

HPMA copolymer conjugate with pirarubicin: In vitro and ex vivo stability and drug release study

development, here we report THP release profile from its HPMA copolymer conjugate, the conjugate stability ...

International journal of pharmaceutics. 2018 Jan 30 ; 536 (1) : 108-115. [epub] 20171110

Int J Pharm
ISSN 1873-3476 | 0378-5173
Zdroj

We have developed a tumor environment-responsive polymeric anticancer prodrug containing pirarubicin (THP) conjugated to N-(2-hydroxypropyl) methacrylamide copolymer (PHPMA), [P-THP], through a spacer containing pH-sensitive hydrazone bond, that showed remarkable therapeutic effect against various tumor models and in a human pilot study. Toward clinical development, here we report THP release profile from its HPMA copolymer conjugate, the conjugate stability, protein and cell-binding and solubility of P-THP. Size exclusion chromatography of P-THP (molecular weight 38 kDa) showed similar hydrodynamic volume as bovine serum albumin (BSA) in aqueous solution, with no apparent interactions with BSA, nor aggregation by itself. pH-responsive release of free THP was reconfirmed at pHs 6.5 and lower. The drug release was significantly affected by a type of used buffer. Phosphate buffer seems to facilitate faster hydrazone bond cleavage at pH 7.4 whereas higher stability was achieved in L-arginine solution which yielded only little cleavage and THP release, approx. 15% within 2 weeks at the same pH at 25 °C. Furthermore, ex vivo study using sera of different animal species showed very high stability of P-THP. Incubation with blood showed high stability of P-THP during circulation, without binding to blood cells. These findings revealed that L-arginine solution provides appropriate media for formulation of P-THP infusion solution as tumor-targeted polymeric anticancer drug based on EPR effect.

Klíčová slova
Arginine, EPR effect, HPMA copolymer, Stability, Tumor environment responsive, Tumor-targeting,
MeSH
arginin chemie MeSH
doxorubicin analogy a deriváty chemie MeSH
králíci MeSH
krysa rodu Rattus MeSH
lidé MeSH
methakryláty chemie MeSH
myši MeSH
nosiče léků chemie MeSH
pilotní projekty MeSH
polymery chemie MeSH
protinádorové látky chemie MeSH
rozpustnost účinky léků MeSH
sérový albumin hovězí chemie MeSH
uvolňování léčiv účinky léků MeSH
zvířata MeSH
Check Tag
králíci MeSH
krysa rodu Rattus MeSH
lidé MeSH
myši MeSH
zvířata MeSH
Publikační typ
časopisecké články MeSH
Názvy látek
arginin MeSH
doxorubicin MeSH
hydroxypropyl methacrylate MeSH Prohlížeč
methakryláty MeSH
nosiče léků MeSH
pirarubicin MeSH Prohlížeč
polymery MeSH
protinádorové látky MeSH
sérový albumin hovězí MeSH

Článek

Bloodstream Stability Predetermines the Antitumor Efficacy of Micellar Polymer-Doxorubicin Drug Conjugates with pH-Triggered Drug Release

amphiphilic N-(2-hydroxypropyl) methacrylamide (HPMA)-based polymer conjugates with the anticancer drug ...

Molecular pharmaceutics. 2018 Sep 04 ; 15 (9) : 3654-3663. [epub] 20180321

Mol Pharm
ISSN 1543-8392 | 1543-8384
Zdroj

Herein, the biodegradable micelle-forming amphiphilic N-(2-hydroxypropyl) methacrylamide (HPMA)-based polymer conjugates with the anticancer drug doxorubicin (Dox) designed for enhanced tumor accumulation were investigated, and the influence of their stability in the bloodstream on biodistribution, namely, tumor uptake, and in vivo antitumor efficacy were evaluated in detail. Dox was attached to the polymer carrier by a hydrazone bond enabling pH-controlled drug release. While the polymer-drug conjugates were stable in a buffer at pH 7.4 (mimicking bloodstream environment), Dox was released in a buffer under mild acidic conditions modeling the tumor microenvironment or cells. The amphiphilic polymer carriers differed in the structure of hydrophobic cholesterol derivative moieties bound to the HPMA copolymers via a hydrolyzable hydrazone bond, exhibiting different rates of micellar structure disintegration at various pH values. Considerable dependence of the studied polymer-drug conjugate biodistribution on the stability of the micellar structure was observed in neutral, bloodstream-mimicking, environment, showing that a faster rate of the micelle disintegration in pH 7.4 increased the conjugate blood clearance, decreased tumor accumulation, and significantly reduced the tumor:blood and tumor:muscle ratios. Similarly, the final therapeutic outcome was strongly affected by the stability of the micellar structure because the most stable micellar conjugate showed an almost similar therapeutic outcome as the water-soluble, nondegradable, high-molecular-weight starlike HPMA copolymer-Dox conjugate, which was highly efficient in the treatment of solid tumors in mice. Based on the results, we conclude that the bloodstream stability of micellar polymer-anticancer drug conjugates, in addition to their low side toxicity, is a crucial parameter for their efficient solid tumor accumulation and high in vivo antitumor activity.